MIRENA 52 mg Intrauterine

INSTRUCTIONS for medical use of the medicinal product THIOTRIAZOLIN

Composition

active substance: thiotriazolin; 1 ml of solution contains morpholine salt of thiazothic acid (thiotriazolin) in terms of 100% substance – 10 mg; 1 ml of solution contains 20 drops; excipients: sodium chloride, methylcellulose, water for injections.

Pharmaceutical form

Eye drops.

Main physical and chemical properties

Slightly opalescent, colorless or with a slightly yellowish tint liquid.

Pharmacotherapeutic group

Ophthalmological agents. ATC code S01X A.

Pharmacological properties

Pharmacodynamics

The pharmacological effect of thiotriazolin is due to the activation of the antioxidant system of enzymes and the inhibition of lipid peroxidation processes in ischemic areas of eye tissues, reduction of the severity of neurotrophic disorders, increase in the intensity and rate of reparative processes, reduction of inflammatory reactions of tissues, improvement of blood flow in the microcirculatory bed of the eye. The preparation promotes early recovery of corneal sensitivity, formation of a more delicate haze, significant reduction of various complications, reduces manifestations of visual asthenopia, improves functional indicators of the accommodative muscle and central parts of the retina, which improves the functional ability of the eyes.

Pharmacokinetics

Not studied.

Clinical characteristics

Indications

Eye injuries and burns, inflammatory and dystrophic diseases of the cornea, viral conjunctivitis. For the prevention of eye inflammation, reduction of visual asthenopia in individuals working with personal computers.

Contraindications

Increased sensitivity to the preparation.

Interaction with other medicinal products and other types of interactions

Unknown.

Special warnings and precautions for use

None.

Use during pregnancy or breastfeeding

No contraindications.

Ability to influence the reaction rate when driving vehicles or operating other mechanisms

Does not affect.

Method of administration and dosage

The preparation is prescribed from the first days of the disease in the form of instillation of 2 drops 3-4 times a day into the conjunctival sac of the affected eye.

Instillations of Thiotriazolin are carried out for 14-15 days. If necessary, the treatment course can be extended to 30 days.

For individuals working with personal computers, the preparation is prescribed in the form of instillations of 2 drops immediately before the start of work, and then every 2 hours. The duration of application is determined individually by the doctor.

Since the preparation is stored at a temperature of 2-8 °C after opening the vial, it must be warmed to room temperature before use.

Children

There is no experience with the use of the preparation in children, so it is not recommended to prescribe the preparation to this age group of patients.

Overdose

When following the recommended doses, overdose is impossible.

Adverse reactions

Usually, the preparation is well tolerated, possible reactions at the site of administration. With increased individual sensitivity, allergic reactions are possible, including itching, hyperemia.

There have been reports of non-serious adverse events.

Shelf life

2 years.

After opening the vial, store at a temperature between 2 °C and 8 °C for 5 days.

Storage conditions

Store in the original packaging at a temperature not exceeding 25 °C.

Store in a place inaccessible to children.

Packaging

1 vial with a dropper cap in a pack.

Release category

By prescription.

Manufacturer

Joint-Stock Company "Kyivmedpreparat).

Location of the manufacturer and address of the place of business

Ukraine, 01032, Kyiv, Saksaganskogo Street, 139.